Replies to post #3370 on Galectin Therapeutics Inc. (GALT)

[Amatuer17]

They do not drop out of tree but are planned

Look another NASH CO used the opportunity today

“Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today announced that it has priced its previously announced underwritten public offering of 5,000,000 ordinary shares, at a public offering price of $15.00 per share. The gross proceeds to Galmed, before deducting the underwriting discounts and commissions and estimated offering expenses will be $75 million...”